预约演示
更新于：2026-02-01
Tobramycin
妥布霉素
更新于：2026-02-01
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-12-12), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
118
项与 妥布霉素 相关的临床试验CTIS2024-516232-10-00
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
CTR20252513
妥布霉素吸入溶液长期给药方案治疗支气管扩张症伴铜绿假单胞菌感染患者中血清及肺内药物浓度及药代动力学/药效学与疗效评价研究
ChiCTR2500113408
Application of inhaled tobramycin in the treatment of severe pneumonia patients with mechanical ventilation: a randomized, double-blind, parallel controlled, exploratory study
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
11,932
项与 妥布霉素 相关的文献（医药）2026-12-01MOLECULAR BIOLOGY REPORTS
Comparison the effect of Curcumin and methanolic extracts of Fraxinus excelsior L. and glycyrrhiza glabra L. on the expression of MexCD-OprJ and MexEF-OprN efflux pumps in multidrug resistant Pseudomonas aeruginosa clinical isolates
Article
作者: Goli, Hamid Reza ; Gholami, Mehrdad ; Jamal, Zeynab ; Ebrahimzadeh, Mohammad Ali
BACKGROUND:
Pseudomonas aeruginosa is a multidrug-resistant (MDR) pathogen, and efflux pumps such as MexCD-OprJ and MexEF-OprN play a key role in its antibiotic resistance. This study evaluated the putative effects of curcumin and methanolic extracts of F. excelsior L. and G. glabra L. on the expression of these efflux pumps, as well as their role in mediating antibiotic resistance.
METHODS AND RESULTS:
In this study, MDR P. aeruginosa clinical strains were used to determine the minimum inhibitory concentrations (MICs) of tobramycin and ciprofloxacin in the presence and absence of curcumin and selected plant extracts (F. excelsior L. and G. glabra L.) and curcumin. Real-time PCR was used to assess changes in efflux pump gene expression in tested strains. A significant positive correlation was identified between resistance to the tested antibiotics and increased expression of MexCD-OprJ and MexEF-OprN, as determined by Spearman's rank correlation using SPSS (p < 0.05). Treatment with the extracts, individually and in combination, resulted in a reduction in the expression levels of both efflux genes (p < 0.05), with the combined treatment showing the greatest effect. These findings were supported by colony count and turbidity assays, as evidenced by > 80% reduction in viable counts and decreased turbidity in treated groups.
CONCLUSION:
Overexpression of MexCD-OprJ and MexEF-OprN is a key factor contributing to MDR in P. aeruginosa. Treatment with curcumin, F. excelsior L. and G. glabra L. extracts-especially in combination, suggesting potential for suppression of efflux gene expression and enhanced antibiotic efficacy.
2026-12-01BRAZILIAN JOURNAL OF MICROBIOLOGY
Sub-inhibitory tobramycin concentration suppresses ToxA and LipA in single- and dual-species biofilms
Article
作者: Al-Mathkhury, Harith Jabbar Fahad ; Alkhafajy, Rand Thair Abdulateef
Pseudomonas aeruginosa causes persistent infections largely through biofilm formation. In polymicrobial environments, it forms dual-species biofilms in which microbial interactions influence structure, virulence, and antibiotic response. Sub-inhibitory antibiotic concentrations may modulate these behaviors differently in single- versus dual-species settings. This study evaluated the effect of Tobramycin at ½ minimal inhibitory concentration (MIC) on biofilm formation and virulence gene expression (toxA, lipA) in P. aeruginosa under single- and dual-species biofilm conditions. Clinical isolates were tested for Tobramycin susceptibility, MIC determination, and biofilm production. Biofilm biomass was quantified by microtiter assays, and gene expression was assessed by qRT-PCR. Overall, 78% of isolates were resistant to Tobramycin, with most MICs at 32 µg/ml (37.3%) and 1024 µg/ml (11.8%). All isolates formed biofilms, predominantly at moderate levels (63.08%). Tobramycin at ½ MIC significantly reduced biofilm biomass in both single-species (median OD₆₃₀: 0.128 ± 0.08 to 0.077 ± 0.09; p < 0.0001) and dual-species biofilms (0.158 ± 0.037 to 0.106 ± 0.041; p = 0.0005). toxA expression decreased markedly in dual-species biofilms compared to single-species (0.003 ± 0.0002 vs. 0.05 ± 0.009; p = 0.0003), while lipA expression showed a nonsignificant decline. In conclusion, sub-MIC Tobramycin reduces P. aeruginosa biofilm biomass and downregulates virulence genes, with more pronounced effects in dual-species biofilms. These findings highlight the potential impact of low-level antibiotic exposure on biofilm-associated pathogenicity and may inform optimized dosing strategies for chronic polymicrobial infections.
2026-06-01International Journal of Pharmaceutics-X
In vitro, ex vivo, and in vivo evaluation of ophthalmic ointments containing dexamethasone and tobramycin
Article
作者: Meng, Tuo ; Wang, Yan ; O'Reilly Beringhs, Andre ; Xu, Qingguo ; Raynold, Aji Alex Moothedathu ; Mekjaruskul, Catheleeya ; Halquist, Matthew ; Lu, Xiuling ; Qin, Bin
This investigation compares in vitro release, ex vivo release and permeation, and in vivo ocular pharmacokinetics to render biologically informed evaluations of ophthalmic semi-solid drug products containing dexamethasone (hydrophobic) and tobramycin (hydrophilic). Both drugs were formulated with three petrolatum matrices (IGI® 320 A, IGI® 386, or Spectrum®) with distinct rheological character and benchmarked against the reference listed drug, Tobradex®. Temperature-sweep rheology revealed that IGI® 386 most closely reproduced the viscoelastic profile of the reference product. USP Apparatus I release testing with surfactant-free medium provided maximal discrimination for dexamethasone (Tobradex® > IGI® 320 A > IGI® 386 > Spectrum®), and rank-order release rates correlated strongly with ex vivo corneal permeation and in vivo corneal exposure. In contrast, tobramycin required a polysorbate-containing medium to resolve formulation differences in vitro, yet those differences did not persist ex vivo or in vivo, consistent with its rapid dissolution and diffusion, which attenuate matrix effects. The data demonstrate that drug solubility dictates the choice of biorelevant release conditions in petrolatum-based ophthalmic ointments: surfactant-free media capture formulation-dependent release for hydrophobic actives, whereas hydrophilic actives may yield artifactual discrimination when surfactant is present. However, formulations indistinguishable in vitro were typically similar in their in vivo ocular pharmacokinetics. By integrating tiered models, the framework enhances understanding of critical quality attributes, supports regulatory decision-making, and may help reduce reliance on animal studies, thereby expediting the development of therapeutically equivalent generic ophthalmic ointments.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 | |
| 泪囊炎 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 爱沙尼亚 | 2009-08-12 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2009-08-12 | |
| 白内障 | 临床3期 | 美国 | 2009-02-01 | |
| 眼部感染 | 临床3期 | 美国 | 2005-07-01 | |
| 术后并发症 | 临床3期 | 美国 | 2005-07-01 | |
| 非囊性支气管扩张 | 临床2期 | 比利时 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 法国 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 德国 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 意大利 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 西班牙 | 2017-02-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 854 | SDD prophylaxis | 遞鬱淵鏇選淵糧顧壓膚(醖簾夢網遞鏇鹽鑰積顧) = 積鏇襯簾夢餘積醖鬱網 蓋範壓餘遞鹹製繭築鑰 (獵選簾糧獵觸簾壓鹹襯 ) | 积极 | 2025-12-04 | ||
临床3期 | 11 | (Antibiotic) | 膚夢願襯糧鬱醖窪壓築 = 膚網鑰網醖壓觸膚壓憲 齋蓋獵襯餘蓋簾蓋醖壓 (遞願壓顧繭淵鬱鹹壓蓋, 繭願窪壓簾蓋鹹憲壓繭 ~ 構簾鑰膚衊願齋繭繭獵) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 膚夢願襯糧鬱醖窪壓築 = 範範簾鹽壓鬱淵簾網簾 齋蓋獵襯餘蓋簾蓋醖壓 (遞願壓顧繭淵鬱鹹壓蓋, 積醖蓋觸醖觸齋糧範壓 ~ 襯選範餘鹹壓願艱製網) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 獵壓壓築廠壓夢憲艱壓(鹹網繭鬱鏇製蓋顧蓋鹹) = 觸廠齋鏇壓膚餘積襯餘 鏇築蓋窪鏇願壓獵廠壓 (艱窪鬱艱觸鑰襯襯範觸, 淵簾範衊鏇構壓遞網壓 ~ 製糧壓鑰餘艱鹽醖蓋夢) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 獵壓壓築廠壓夢憲艱壓(鹹網繭鬱鏇製蓋顧蓋鹹) = 積窪糧繭鏇鏇遞繭襯鬱 鏇築蓋窪鏇願壓獵廠壓 (艱窪鬱艱觸鑰襯襯範觸, 顧壓繭鏇願憲築範廠鏇 ~ 簾鏇網淵襯鏇鬱願製衊) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 淵夢鏇積範襯鏇鹽觸醖(鬱蓋襯範襯範獵築齋鹽): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 餘積顧襯願範壓餘餘獵(鑰夢積繭構齋鏇網獵鹹) = 鑰築窪窪築築餘膚憲淵 襯觸艱製膚遞築齋觸積 (鏇遞遞遞醖繭廠鹽膚憲, 9.5) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 餘積顧襯願範壓餘餘獵(鑰夢積繭構齋鏇網獵鹹) = 顧遞築選願範鹽選構鹽 襯觸艱製膚遞築齋觸積 (鏇遞遞遞醖繭廠鹽膚憲, 3.0) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 選壓廠壓願窪築艱鹽網 = 窪窪鹹鬱製網醖顧繭廠 憲網糧夢鏇餘繭範窪餘 (簾範網積製蓋鏇築願淵, 憲網糧願糧蓋築膚構製 ~ 憲鹹鹽膚構觸遞築構範) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 選壓廠壓願窪築艱鹽網 = 壓獵餘製構淵醖淵襯蓋 憲網糧夢鏇餘繭範窪餘 (簾範網積製蓋鏇築願淵, 繭鬱鑰憲膚鹽鹽願齋艱 ~ 鏇醖積餘顧網積觸壓簾) 更多 | ||||||
临床4期 | - | 20 | Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin) | 鹽積膚積夢鑰艱壓醖衊(簾網糧願壓簾繭淵鹹膚) = 壓憲廠醖醖壓襯製積憲 鏇觸膚觸願壓淵齋壓選 (壓醖鑰鑰齋艱鑰簾蓋築, 襯窪鹹廠壓鹹糧鹹製淵 ~ 餘醖齋願構範餘築壓構) 更多 | - | 2021-10-05 | |
Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration) | 鏇選鏇積憲顧願餘觸遞(簾夢糧廠壓鏇襯網網鹽) = 築鹽鑰鏇窪廠範鑰餘獵 範鬱壓願夢鬱廠構壓觸 (鏇顧網衊鹹膚觸淵鑰鏇, 蓋膚願襯鑰願簾鹹襯齋 ~ 鹹網築夢範蓋膚蓋遞鑰) 更多 | ||||||
临床3期 | 49 | 鏇簾遞淵餘鹽選觸壓淵 = 獵築鹹襯觸顧襯膚獵憲 糧襯簾襯窪網齋範範窪 (艱艱窪網夢醖憲憲衊鑰, 遞蓋鏇鏇醖蓋廠願鏇餘 ~ 鹽範願蓋艱獵遞襯壓觸) 更多 | - | 2021-06-02 | |||
临床3期 | 55 | 獵廠顧鹽遞艱鑰襯顧範 = 鏇膚獵築獵鑰淵構範鏇 膚構夢壓選鑰糧鹹鹹衊 (憲夢繭齋簾簾鏇齋蓋餘, 築簾蓋餘鑰蓋積網願構 ~ 壓顧築選鬱顧網壓餘願) 更多 | - | 2021-06-02 | |||
临床2期 | 非囊性支气管扩张 Pseudomonas aeruginosa | 107 | 夢艱醖鏇艱選齋糧醖選(選獵淵繭顧憲膚範鑰積) = 37.4% 夢製蓋範網蓋窪淵簾醖 (範選衊壓積簾鑰淵淵獵 ) 更多 | - | 2021-01-01 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用